Sexually Transmitted Disease (STD) Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Disease (Chlamydia, Syphilis, Gonorrhea, Hyper Simplex Virus Human Immunodeficiency Virus, Chancroid); By Loca

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	200 Pages	BlueWeave Consulting	January, 2023	BLWC17631039

Best Price Guarantee
Price	from $4,850
Length	200 Pages
Publisher	BlueWeave Consulting
Published Date	January, 2023
SKU	BLWC17631039

Sexually Transmitted Disease (STD) Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Disease (Chlamydia, Syphilis, Gonorrhea, Hyper Simplex Virus Human Immunodeficiency Virus, Chancroid); By Location (Laboratory, Point of Care (PoC)); By Device (Laboratory Devices, Point of Care (PoC) Devices); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Sexually Transmitted Disease Testing Market Size Expands to Cross USD 135.5 Billion by 2029
Global sexually transmitted disease (STD) testing market is flourishing because of an increasing prevalence and rising incidences of STDs, growing establishment of national screening programs, and rising support for STD testing reimbursements across the globe.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global sexually transmitted disease (STD) testing market size at USD 91.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global sexually transmitted disease testing market size to grow at a steady CAGR of 6.2% reaching a value of USD 135.5 billion by 2029. Major factors for the expansion of global sexually transmitted disease testing market include increasing public awareness and patient education, global rise in the incidence of sexually transmitted illnesses, increasing patient awareness through education campaigns, and a surge in government activities. The prevalence and incidence of sexually transmitted illnesses have increased significantly during the previous decade. As the frequency of sexually transmitted illnesses increases, countries worldwide are focused on the deployment of national screening programs to expand the coverage of sexually transmitted disease diagnosis. Also, the payment regulations for services related to sexually transmitted diseases have been favorable. Technology advancements and developments in the diagnosis of STDs are also projected to boost market expansion. Increased national screening program implementation to increase sexually transmitted disease diagnosis coverage will also boost the demand for STDs testing. These reasons are considerably driving the growth of the global sexually transmitted diseases testing market. However, social stigma associated with patients visiting specialized STD clinics and huge protection of patients infected with STDs in remotes areas are anticipated to hinder the market growth during the period in analysis.
Global Sexually Transmitted Disease Testing Market – Overview

Sexual health testing is a collection of diverse tests and procedures used to diagnose and detect sexually transmitted illnesses, such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and others. For sexual health testing, four major types of testing are employed, including Culture/Isolation of Organisms, Molecular Test, Immunology Assay, and others. HIV can be diagnosed using one of three HIV tests: antibody testing, antigen/antibody tests, and nucleic acid tests (NAT). STD prevalence and incidence have risen considerably in the recent decade. As the prevalence of sexually transmitted illnesses rises, nations around the world are focusing on developing nationwide screening programs to increase the adoption of sexually transmitted disease diagnostics coverage. Reimbursement regulations for diagnostic services for sexually transmitted diseases have been useful. These factors are significantly contributing to the growth of the global sexually transmitted diseases diagnostics market.

Impact of COVID-19 on Global Sexually Transmitted Disease Testing Market
COVID-19 adversely affected the STD (sexually transmitted disease) testing market. Due to disruptions in healthcare and STD testing facilities, the CDC (Centers for Disease Control and Prevention) observed a decline in STD testing during the early months of COVID-19. Few members may have unwittingly disseminated the virus due to inadequate testing and diagnosis. As a result, even though the transmission of STDs rose during the pandemic, the market value declined due to the decrease in testing. STD testing surged once the lockdown and travel ban were lifted, and the market is projected to boost the expansion of market growth.
Global Sexually Transmitted Disease Testing Market – By Location
Based on location, global sexually transmitted disease testing market is bifurcated in Laboratory and Point of Care (PoC). In 2022, the laboratory testing segment had a higher market share, but PoC testing is expected to rise at a faster rate in the years ahead. Laboratory testing includes commercial/private labs and public health labs. Laboratory testing is a time-consuming but more exact procedure that involves commercial/private labs as well as public health labs. Likewise, the PoC segment includes testing kits, is faster, the results may be less exact. However, bedside testing or mobile testing that allows for rapid healthcare provision for patients is capturing market share. There has been a major transition from traditional laboratory tests to rapid and easy point of care tests, due to the benefits provided by point of care testing equipment.

Competitive Landscape
Major players operating in global sexually transmitted disease testing market include Abbott Laboratories, BioMérieux, Inc., Becton Dickinson Company, Danaher Corporation, Bio-Rad Laboratories, Inc., Hologic, Inc., Diasorin Molecular LLC, Roche Holding AG, Orasure Technologies, Inc., Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, and Merck and Co. Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Sexually Transmitted Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Sexually Transmitted Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

1. Research Framework: 1.1. Research Objective; 1.2. Product Overview; 1.3. Market Segmentation
2. Executive Summary
3. Global Sexually Transmitted Disease Testing Market Insights: 3.1. Industry Value Chain Analysis; 3.2. DROC Analysis; 3.2.1. Growth Drivers; 3.2.1.1. High Prevalence & Rise in Incidences of STD across the Globe; 3.2.1.2. Implementation of National Screening Programs; 3.2.1.3. Supporting Reimbursement of STDs Testing; 3.2.2. Restraints; 3.2.2.1. Social Stigma Associated with Patients Visiting Specialized STD Clinics; 3.2.2.2. Huge Protection of Patients Infected with STDs in Remotes Areas; 3.2.3. Opportunities; 3.2.3.1. Decrease In Number of Visits to Government Clinics; 3.2.3.2. National Screening Programs Across the Globe; 3.2.3.3. Niche Opportunities for Technology and POC Test Providers in an Emerging Economy; 3.2.4. Challenges; 3.2.4.1. Stringent Regulations; 3.3. Technology Advancements/Recent Developments; 3.4. Regulatory Framework; 3.5. Porter’s Five Forces Analysis; 3.5.1. Bargaining Power of Suppliers; 3.5.2. Bargaining Power of Buyers; 3.5.3. Threat of New Entrants; 3.5.4. Threat of Substitutes; 3.5.5. Intensity of Rivalry
4. Global Sexually Transmitted Disease Testing Market Overview: 4.1. Market Size & Forecast by Value, 2019–2029; 4.1.1. By Value (USD Million); 4.2. Market Share & Forecast; 4.2.1. By Disease; 4.2.1.1. Chlamydia; 4.2.1.2. Syphilis; 4.2.1.3. Gonorrhoea; 4.2.1.4. Hyper Simplex Virus; 4.2.1.5. Human Immunodeficiency Virus; 4.2.1.6. Chancroid; 4.2.1.7. Others; 4.2.2. By Location; 4.2.2.1. Laboratory; 4.2.2.1.1. Commercial/Private Labs; 4.2.2.1.2. Public Health Labs; 4.2.2.2. Point of Care (POC); 4.2.3. By Device; 4.2.3.1. Laboratory Devices; 4.2.3.1.1. Thermal Cyclers PCR; 4.2.3.1.2. Lateral Flow Readers- Immune Chromatographic Arrays; 4.2.3.1.3. Flow Cytometers; 4.2.3.1.4. Differential Light Scattering Machines; 4.2.3.1.5. Absorbance Micro Plate Reader- Enzyme- Linked Immunosorbent Assay (ELISA); 4.2.3.1.6. Others; 4.2.3.2. Point of Care (POC) Devices; 4.2.4. By Region; 4.2.4.1. North America; 4.2.4.2. Europe; 4.2.4.3. Asia Pacific; 4.2.4.4. Latin America; 4.2.4.5. Middle East and Africa
5. North America Sexually Transmitted Disease Testing Market: 5.1. Market Size & Forecast by Value, 2019–2029; 5.1.1. By Value (USD Million); 5.2. Market Share & Forecast; 5.2.1. By Disease; 5.2.2. By Location; 5.2.3. By Device; 5.2.4. By Country; 5.2.4.1. US; 5.2.4.1.1. By Disease; 5.2.4.1.2. By Location; 5.2.4.1.3. By Device; 5.2.4.2. Canada; 5.2.4.2.1. By Disease; 5.2.4.2.2. By Location; 5.2.4.2.3. By Device
6. Europe Sexually Transmitted Disease Testing Market: 6.1. Market Size & Forecast by Value, 2019–2029; 6.1.1. By Value (USD Million); 6.2. Market Share & Forecast; 6.2.1. By Disease; 6.2.2. By Location; 6.2.3. By Device; 6.2.4. By Country; 6.2.4.1. Germany; 6.2.4.1.1. By Disease; 6.2.4.1.2. By Location; 6.2.4.1.3. By Device; 6.2.4.2. UK; 6.2.4.2.1. By Disease; 6.2.4.2.2. By Location; 6.2.4.2.3. By Device; 6.2.4.3. Italy; 6.2.4.3.1. By Disease; 6.2.4.3.2. By Location; 6.2.4.3.3. By Device; 6.2.4.4. France; 6.2.4.4.1. By Disease; 6.2.4.4.2. By Location; 6.2.4.4.3. By Device; 6.2.4.5. Spain; 6.2.4.5.1. By Disease; 6.2.4.5.2. By Location; 6.2.4.5.3. By Device; 6.2.4.6. The Netherlands; 6.2.4.6.1. By Disease; 6.2.4.6.2. By Location; 6.2.4.6.3. By Device; 6.2.4.7. Rest of Europe; 6.2.4.7.1. By Disease; 6.2.4.7.2. By Location; 6.2.4.7.3. By Device
7. Asia-Pacific Sexually Transmitted Disease Testing Market: 7.1. Market Size & Forecast by Value, 2019–2029; 7.1.1. By Value (USD Million); 7.2. Market Share & Forecast; 7.2.1. By Disease; 7.2.2. By Location; 7.2.3. By Device; 7.2.4. By Country; 7.2.4.1. China; 7.2.4.1.1. By Disease; 7.2.4.1.2. By Location; 7.2.4.1.3. By Device; 7.2.4.2. India; 7.2.4.2.1. By Disease; 7.2.4.2.2. By Location; 7.2.4.2.3. By Device; 7.2.4.3. Japan; 7.2.4.3.1. By Disease; 7.2.4.3.2. By Location; 7.2.4.3.3. By Device; 7.2.4.4. South Korea; 7.2.4.4.1. By Disease; 7.2.4.4.2. By Location; 7.2.4.4.3. By Device; 7.2.4.5. Australia & New Zealand; 7.2.4.5.1. By Disease; 7.2.4.5.2. By Location; 7.2.4.5.3. By Device; 7.2.4.6. Indonesia; 7.2.4.6.1. By Disease; 7.2.4.6.2. By Location; 7.2.4.6.3. By Device; 7.2.4.7. Malaysia; 7.2.4.7.1. By Disease; 7.2.4.7.2. By Location; 7.2.4.7.3. By Device; 7.2.4.8. Singapore; 7.2.4.8.1. By Disease; 7.2.4.8.2. By Location; 7.2.4.8.3. By Device; 7.2.4.9. Philippines; 7.2.4.9.1. By Disease; 7.2.4.9.2. By Location; 7.2.4.9.3. By Device; 7.2.4.10. Vietnam; 7.2.4.10.1. By Disease; 7.2.4.10.2. By Location; 7.2.4.10.3. By Device; 7.2.4.11. Rest of APAC; 7.2.4.11.1. By Disease; 7.2.4.11.2. By Location; 7.2.4.11.3. By Device
8. Latin America Sexually Transmitted Disease Testing Market: 8.1. Market Size & Forecast by Value, 2019–2029; 8.1.1. By Value (USD Million); 8.2. Market Share & Forecast; 8.2.1. By Disease; 8.2.2. By Location; 8.2.3. By Device; 8.2.4. By Country; 8.2.4.1. Brazil; 8.2.4.1.1. By Disease; 8.2.4.1.2. By Location; 8.2.4.1.3. By Device; 8.2.4.2. Mexico; 8.2.4.2.1. By Disease; 8.2.4.2.2. By Location; 8.2.4.2.3. By Device; 8.2.4.3. Argentina; 8.2.4.3.1. By Disease; 8.2.4.3.2. By Location; 8.2.4.3.3. By Device; 8.2.4.4. Peru; 8.2.4.4.1. By Disease; 8.2.4.4.2. By Location; 8.2.4.4.3. By Device; 8.2.4.5. Colombia; 8.2.4.5.1. By Disease; 8.2.4.5.2. By Location; 8.2.4.5.3. By Device; 8.2.4.6. Rest of LATAM; 8.2.4.6.1. By Disease; 8.2.4.6.2. By Location; 8.2.4.6.3. By Device
9. Middle East & Africa Sexually Transmitted Disease Testing Market: 9.1. Market Size & Forecast by Value, 2019–2029; 9.1.1. By Value (USD Million); 9.2. Market Share & Forecast; 9.2.1. By Disease; 9.2.2. By Location; 9.2.3. By Device; 9.2.4. By Country; 9.2.4.1. Saudi Arabia; 9.2.4.1.1. By Disease; 9.2.4.1.2. By Location; 9.2.4.1.3. By Device; 9.2.4.2. UAE; 9.2.4.2.1. By Disease; 9.2.4.2.2. By Location; 9.2.4.2.3. By Device; 9.2.4.3. Qatar; 9.2.4.3.1. By Disease; 9.2.4.3.2. By Location; 9.2.4.3.3. By Device; 9.2.4.4. Kuwait; 9.2.4.4.1. By Disease; 9.2.4.4.2. By Location; 9.2.4.4.3. By Device; 9.2.4.5. South Africa; 9.2.4.5.1. By Disease; 9.2.4.5.2. By Location; 9.2.4.5.3. By Device; 9.2.4.6. Nigeria; 9.2.4.6.1. By Disease; 9.2.4.6.2. By Location; 9.2.4.6.3. By Device; 9.2.4.7. Algeria; 9.2.4.7.1. By Disease; 9.2.4.7.2. By Location; 9.2.4.7.3. By Device; 9.2.4.8. Rest of MEA; 9.2.4.8.1. By Disease; 9.2.4.8.2. By Location; 9.2.4.8.3. By Device
10. Competitive Landscape: 10.1. List of Key Players and Their Offerings; 10.2. Global Sexually Transmitted Disease Testing Company Market Share Analysis, 2022; 10.3. Competitive Benchmarking, By Operating Parameters; 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Sexually Transmitted Disease Testing Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis): 12.1. Abbott Laboratories; 12.2. BioMérieux, Inc.; 12.3. Becton Dickinson Company; 12.4. Danaher Corporation; 12.5. Bio-Rad Laboratories, Inc.; 12.6. Hologic, Inc.; 12.7. Diasorin Molecular LLC; 12.8. Roche Holding AG; 12.9. Orasure Technologies, Inc.,; 12.10. Thermo Fisher Scientific Inc.; 12.11. AccuBioTech Co. Ltd.; 12.12. AdvaCare Pharma; 12.13. BIOGENIX Inc. Pvt. Ltd.; 12.14. CTK Biotech Inc.; 12.15. Everlywell Inc.; 12.16. F. Hoffmann La Roche Ltd.; 12.17. Gilead Sciences Inc.; 12.18. GlaxoSmithKline Plc; 12.19. Merck and Co. Inc.; 12.20. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology: 14.1. Qualitative Research; 14.1.1. Primary & Secondary Research; 14.2. Quantitative Research; 14.3. Market Breakdown & Data Triangulation; 14.3.1. Secondary Research; 14.3.2. Primary Research; 14.4. Breakdown of Primary Research Respondents, By Region; 14.5. Assumption & Limitation

Sexually Transmitted Disease (STD) Diagnostics Market Report by Type (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing, and Others), Device Type (Laboratory Devices, Point of Care (PoC) Devices), End User (Laboratory Testing, Point of Care (PoC) Testing), and Region 2024-2032

April, 2024 | Published by: IMARC Services Pvt. Ltd. | USD $3,899
Global Sexually Transmitted Diseases (STD) Testing Market Size study & Forecast, by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus, Syphilis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), and Other Diseases) and Location of Testing (Laboratory Testing, and Point-of-care (POC) Testing) and Regional Analysis, 2022-2029

November, 2022 | Published by: Bizwit Research & Consulting | USD $4,950
Sexually Transmitted Disease Testing Market Size, Trends, Analysis, and Outlook By Disease (Chlamydia, Gonorrhea, Herpes simplex virus, Syphilis, Human papillomavirus (HPV), Others), By Testing (Laboratory testing, Point of care (POC) testing), by Region, Country, Segment, and Companies, 2024-2030

March, 2024 | Published by: VPA Research | USD $3,980
Sexually Transmitted Disease (STD) Diagnostics Market by Type (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing, and Others), Devic

February, 2023 | Published by: IMARC Services Pvt. Ltd. | USD $2,699
United States Sexually Transmitted Disease (STD) Testing Market, By Disease Type (Chlamydia, Gonorrhea, Genital Herpes, Syphilis, Human Immunodeficiency Virus (HIV), Human papillomavirus (HPV)); By Product Type (Instruments, Reagents & Kits); By Device Type (Laboratory Devices, Point of care (POC) Devices); By End User (Hospital & Clinics, Clinical Laboratories), Trend Analysis, Competitive Landscape & Forecast, 2019–2029

November, 2023 | Published by: BlueWeave Consulting | USD $2,950
Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2024-2032

April, 2024 | Published by: IMARC Services Pvt. Ltd. | USD $3,899

PDF E-mail From Publisher:	$4,850
Multi User License (5-7 Users) Fulfilled by Publisher:	$5,750
Global Site License Fulfilled by Publisher:	$8,150

Sexually Transmitted Disease (STD) Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Disease (Chlamydia, Syphilis, Gonorrhea, Hyper Simplex Virus Human Immunodeficiency Virus, Chancroid); By Loca

Research Assistance

Other tasks

Sexually Transmitted Disease (STD) Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Disease (Chlamydia, Syphilis, Gonorrhea, Hyper Simplex Virus Human Immunodeficiency Virus, Chancroid); By Loca

Sexually Transmitted Disease Testing Market Size, Trends, Analysis, and Outlook By Disease (Chlamydia, Gonorrhea, Herpes simplex virus, Syphilis, Human papillomavirus (HPV), Others), By Testing (Laboratory testing, Point of care (POC) testing), by Region, Country, Segment, and Companies, 2024-2030

Sexually Transmitted Disease (STD) Diagnostics Market by Type (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing, Chancroid Testing, and Others), Devic

Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2024-2032

Research Assistance

Other tasks